Last edition
News about "SunRISe-1 study"
J&J Reports 74% One-Year Disease-Free Survival with INLEXZO in High-Risk NMIBC
Johnson & Johnson reported strong new data from Cohort 4 of the SunRISe-1 study, showing that INLEXZO (gemcitabine intravesical system) achieved a 74 percent one-year disease-free survival rate in patients with BCG-unresponsive, high-risk papillary-only NMIBC, with over 95 percent progression-free and more than 92 percent avoiding bladder removal.
SunRISe-1 Study | 06/12/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy